The Biotav team has more than 30 years of research and development experience, focused on combating various infectious diseases and the production of innovative new drugs. The company applies its unparalleled knowledge to solving complex problems in the production of unique biopharmaceuticals capable of fighting the most dangerous diseases.
Adopting a “One Health” approach that recognizes the interdependence of human, animal, and environmental health, Biotav achieves breakthrough results by adapting its extensive experience in veterinary medicine to human medicine. The most advanced products in the company’s portfolio to date are an oncolytic viral brain cancer drug and an oral COVID-19 vaccine.
Biotav’s multi-disciplinary team has expertise both in the relevant areas of biology, pathology, and biopharmaceutical manufacturing, and in market and regulatory issues. The company has worked in strict compliance with the requirements of c-GMP and the European Pharmacopoeia from the outset.
With provisional patents and pending applications, a first-class GMP manufacturing facility, and a strong network of relationships with leading medical institutions and government agencies, Biotav has all the right ingredients/ elements to implement its unique products into medical practice.